{"slideshow_credits": null, "snippet": "The company said regulators intended to rescind the \u201cbreakthrough therapy\u201d designation for its treatment because other new drugs were available.", "abstract": "Merck & Company announces Food and Drug Administration plans to retract designation of Merck's combination treatment for hepatitis C as 'breakthrough therapy'; decision could delay approval of product for several months.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [], "organization": "REUTERS", "original": "By REUTERS", "contributor": ""}, "web_url": "http://www.nytimes.com/2015/02/05/business/merck-expects-delay-for-a-hepatitis-c-therapy.html", "lead_paragraph": "The company said regulators intended to rescind the \u201cbreakthrough therapy\u201d designation for its treatment because other new drugs were available.", "headline": {"main": "Merck Expects Delay for a Hepatitis C Therapy", "content_kicker": "Business Briefing", "print_headline": "Merck Expects Delay for a Hepatitis C Therapy"}, "_id": "54d2b8fa38f0d81f788a1ef0", "word_count": "89", "multimedia": [], "pub_date": "2015-02-05T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Merck & Company Inc", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Hepatitis", "is_major": "Y", "rank": "2"}, {"name": "organizations", "value": "Food and Drug Administration", "is_major": "N", "rank": "3"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "Brief"}